MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
5.70
-0.81
-12.44%
Closed 19:31 11/17 EST
OPEN
6.11
PREV CLOSE
6.51
HIGH
6.26
LOW
5.70
VOLUME
12.06K
TURNOVER
0
52 WEEK HIGH
29.32
52 WEEK LOW
3.015
MARKET CAP
13.26M
P/E (TTM)
-0.3032
1D
5D
1M
3M
1Y
5Y
1D
Akari: Buy Rating Reiterated as AKTX-101 Advances Toward Phase 1; $27 Price Target Unchanged
TipRanks · 2d ago
Weekly Report: what happened at AKTX last week (1109-1113)?
Weekly Report · 2d ago
Akari Therapeutics reports Q3 results
Seeking Alpha · 4d ago
Weekly Report: what happened at AKTX last week (1102-1106)?
Weekly Report · 11/09 10:22
Weekly Report: what happened at AKTX last week (1026-1030)?
Weekly Report · 11/02 10:21
Akari Therapeutics Expands 2023 Equity Incentive Share Pool
TipRanks · 10/30 21:35
Weekly Report: what happened at AKTX last week (1019-1023)?
Weekly Report · 10/26 10:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 10/19 12:05
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.